SCHEMBL1371689

SCHEMBL1371689

Cc1cc(F)ccc1C[C@@H]1C[C@@H](C(=O)Nc2ccc(Oc3ccc(F)cc3)cc2)N(OC(=O)C(F)(F)F)C1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 9/20 0.46
CYP2C9 P11712 6/20 0.46
CYP2D6 P10635 6/20 0.44
CYP3A4 P08684 3/20 0.44
CFTR P13569 1/20 0.35
EPHX2 P34913 2/20 0.35
HDAC8 Q9BY41 1/20 0.34
HPGD P15428 1/20 0.34
MMP1 P03956 1/20 0.34
MMP13 P45452 1/20 0.34
ADAM17 P78536 1/20 0.34
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
MAPT P10636 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1374795 0.81 S1PR1 (0.52) S1PR1CYP2C9CYP2D6CYP3A4CFTR
SCHEMBL1374798 0.81 S1PR1 (0.52) S1PR1CYP2C9CYP2D6CYP3A4CFTR
SCHEMBL1372044 0.78 S1PR1 (0.77) S1PR1CYP2C9CYP2D6CYP3A4CFTR
Trifluoroacetic Acid SCHEMBL1371687 0.76 F2 (0.38) S1PR1CYP2C9CYP2D6CYP3A4EPHX2
SCHEMBL1371498 0.75 S1PR1 (0.79) S1PR1CYP2C9CYP2D6CYP3A4CFTR
SCHEMBL2173583 0.75 S1PR1 (0.79) S1PR1CYP2C9CYP2D6CYP3A4CFTR
SCHEMBL1372885 0.75 S1PR1 (0.79) S1PR1CYP2C9CYP2D6CYP3A4CFTR
SCHEMBL2186360 0.75 S1PR1 (0.79) S1PR1CYP2C9CYP2D6CYP3A4CFTR
SCHEMBL1372386 0.75 F2 (0.41) S1PR1CYP2C9CYP2D6CYP3A4EPHX2
SCHEMBL2170540 0.75 F2 (0.41) S1PR1CYP2C9CYP2D6CYP3A4EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791102-B2 Acetanilide sphingosine-1-phosphate receptor antagonists EXELIXIS, INC. (US) 2014-07-29 US disclosed
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists EXELIXIS, INC. (US) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists S1PR1, S1PR2, S1PR3 S1PR1 1/4885CYP2C9 4875/4885CYP2D6 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.